MetaCap

Aclaris Therapeutics (ACRS) vs Crescent Biopharma (CBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aclaris Therapeutics (ACRS) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 37.1% versus a loss of 0.5%. Over five years, ACRS leads with a -72.7% price change compared with -92.7% for CBIO. Aclaris Therapeutics is the larger company by market cap ($545.6 million vs $543.2 million), about 1.0 times the size.

Aclaris Therapeutics converts more of its revenue into profit, with a net margin of -829.6% versus -1419.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRS+37.05%CBIO-0.46%
+170%+64%-41%
Nov 21, 20251 yearNov 20, 2026
ACRS-75.05%CBIO-93.09%
+94%-5%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRS versus CBIO key metrics
MetricACRSCBIO
Share price$3.44$13.00
Market cap$545.63M$543.21M
1-day change-1.71%+0.70%
YTD return+14.29%+9.61%
1-year return+37.05%-0.46%
5-year return-72.74%-92.74%
EPS (TTM)$-0.59$-7.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.83M$10.84M
Revenue growth (YoY)-58.19%—
Net income (latest FY)$-64.92M$-153.94M
Gross margin73.28%—
Operating margin-975.91%-1407.52%
Net margin-829.58%-1419.61%
52-week high$6.60$27.41
52-week low$2.46$8.72
Distance from 52-week high-47.88%-52.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+205.23%+148.69%
Average volume3.07M361.17K
Shares outstanding158.61M38.90M
Employees6980
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ACRS has outperformed CBIO by 37.5 percentage points over the past year.
  • Aclaris Therapeutics is more profitable, keeping -829.6 cents of every revenue dollar as net income versus -1419.6 cents for Crescent Biopharma.

About Aclaris Therapeutics

ACRS stock →

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Crescent Biopharma

CBIO stock →

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

ACRS vs CBIO FAQ

Which is bigger, Aclaris Therapeutics or Crescent Biopharma?

Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $545.63M compared with $543.21M for Crescent Biopharma (CBIO).

Which stock has performed better over the past year, ACRS or CBIO?

ACRS returned +37.05% over the past 12 months, compared with -0.46% for CBIO (price return, excluding dividends). Past performance does not predict future results.

Are Aclaris Therapeutics and Crescent Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons